Progensa® PCA3

PCA3 is a gene that is over-expressed in prostate cancer cells. After a digital rectal examination (DRE), PCA3 can be measured in a simple urine sample.


PCA3 is far more specific for prostate cancer than prostate-specific antigen (PSA). Unlike PSA, PCA3 is not influenced by conditions such as benign prostatic hyperplasia (BPH), prostatitis, medical procedures, or injury.

What is the Progensa PCA3 test?

The Progensa PCA3 test is a very sensitive, gene-based urine test. The test is approved by the FDA to help you and your doctor decide is a repeat biopsy is necessary.

If you had a previous prostate biopsy and your result was negative, but your PSA levels remain elevated or continue to rise, the Progensa PCA3 test provides additional, reliable information to make the decision whether you need to undergo a repeat biopsy.

How is the Progensa PCA3 test performed?

After a digital rectal examination (DRE) at your doctor’s office, your doctor will collect a urine sample. Your doctor will then send the sample to the Metamark Genetics laboratory for careful analysis. Metamark will deliver the results of your Progensa PCA3 test to your doctor within 48 – 72 hours.

Want to learn more?

National Comprehensive Cancer Network (NCCN) guidelines
American Urological Association (AUA)



                        Your PCA3 Results
                        The PCA3 Billing Process